24-Hour Induction of Transdermal Buprenorphine to Buprenorphine Extended-Release
2024; Taylor & Francis; Linguagem: Inglês
10.1080/02791072.2024.2430616
ISSN2159-9777
AutoresPouya Azar, Victor W. Li, James S.H. Wong, Mohammadali Nikoo, Jéssica Lígia Picanço Machado, Martha J. Ignaszewski, Nickie Mathew, Amer Raheemullah, Sarah E. Wakeman, Rodney Mullen, Michael Krausz, Julio Montaner, Anil R. Maharaj,
Tópico(s)Pain Management and Opioid Use
ResumoBuprenorphine is an effective treatment for opioid use disorder but can be slow when using a standard low-dose titration protocol to avoid precipitated withdrawal. This presents a substantial practical barrier in clinical practice. Recent low-dose induction strategies have attempted to simplify and shorten the process required for successful induction, including our own transdermal buprenorphine method, which achieves induction to sublingual buprenorphine/naloxone after 48 h. Here, we present two inpatients with active unregulated fentanyl use that were successfully initiated on buprenorphine extended-release with a novel 24-h transdermal buprenorphine protocol without precipitating withdrawal. This protocol may represent a substantial improvement in the practical feasibility of initiating buprenorphine for patients and providers, although further study is required to confirm efficacy and tolerability.
Referência(s)